Cart
sales@molnova.com
MY-1076
CAS No. 3008262-76-5
MY-1076( —— )
Catalog No. M37087 CAS No. 3008262-76-5
MY-1076 is a potent YAP inhibitor with antigastric cancer activity.MY-1076 dose-dependently induced G2/M phase block, induced YAP degradation and apoptosis, and inhibited microtubule protein polymerization.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 67 | In Stock |
|
| 10MG | 107 | In Stock |
|
| 25MG | 211 | In Stock |
|
| 50MG | 337 | In Stock |
|
| 100MG | 538 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMY-1076
-
NoteResearch use only, not for human use.
-
Brief DescriptionMY-1076 is a potent YAP inhibitor with antigastric cancer activity.MY-1076 dose-dependently induced G2/M phase block, induced YAP degradation and apoptosis, and inhibited microtubule protein polymerization.
-
DescriptionMY-1076 is a potent YAP inhibitor with antigastric cancer activity.MY-1076 dose-dependently induced G2/M phase block, induced YAP degradation and apoptosis, and inhibited microtubule protein polymerization.MY-1076 inhibited the proliferation of MGC-803, SGC-7901, HCT-116, and KYSE450 cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | YAP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number3008262-76-5
-
Formula Weight539.57
-
Molecular FormulaC29H33NO9
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC1=C(OC)C=CC(CN(C2=CC(OC)=C(OC)C(OC)=C2)C(/C=C/C3=CC(OC)=C(OC)C(OC)=C3)=O)=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Lexatumumab
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma.
-
STAT3-IN-11
STAT3-IN-11 is a selective STAT3 inhibitor with inhibitory effects on phosphorylation of the STAT3pTyr705 site and phosphorylation of Survivin.
-
HNPMI
HNPMI is an EGFR inhibitor that induces G0/G1 phase arrest of CRC cells in colorectal cancer, regulates enzymes associated with apoptosis, and can promote apoptosis, and can be used for the study of colorectal cancer.
